Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models

Karen Smith, Curtis G. Gemmell, Susan Lang

Research output: Contribution to journal › Article

Abstract

The activity of telavancin was compared with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in planktonic culture and biofilms grown using a range of in vitro models. Antibiotic efficacy was determined using 24 clinical isolates, including healthcare-associated (HA)-MRSA, community-associated (CA)-MRSA and isolates with reduced (intermediate) susceptibility to vancomycin (VISA). Activity against biofilms was compared using three models: 96-peg plates, 96-well flat-bottom plates and a flow-cell system. Cell death was evaluated using a metabolic dye and Live/Dead staining.
Original languageEnglish
Pages (from-to)1327-1332
Number of pages6
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume32
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Vancomycin
Methicillin-Resistant Staphylococcus aureus
Biofilms
Staphylococcus aureus
Cell Death
Coloring Agents
Staining and Labeling
Anti-Bacterial Agents
Delivery of Health Care
In Vitro Techniques
telavancin

Keywords

  • telavancin
  • vancomycin
  • Staphylococcus aureus
  • biofilms

Cite this

Smith, Karen ; Gemmell, Curtis G. ; Lang, Susan. / Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. In: European Journal of Clinical Microbiology and Infectious Diseases. 2013 ; Vol. 32, No. 10. pp. 1327-1332.
@article{d8deac4ce82c490bb9fdffafda41a1c4,
title = "Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models",
abstract = "The activity of telavancin was compared with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in planktonic culture and biofilms grown using a range of in vitro models. Antibiotic efficacy was determined using 24 clinical isolates, including healthcare-associated (HA)-MRSA, community-associated (CA)-MRSA and isolates with reduced (intermediate) susceptibility to vancomycin (VISA). Activity against biofilms was compared using three models: 96-peg plates, 96-well flat-bottom plates and a flow-cell system. Cell death was evaluated using a metabolic dye and Live/Dead staining.",
keywords = "telavancin, vancomycin, Staphylococcus aureus, biofilms",
author = "Karen Smith and Gemmell, {Curtis G.} and Susan Lang",
year = "2013",
month = "10",
doi = "10.1007/s10096-013-1883-z",
language = "English",
volume = "32",
pages = "1327--1332",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer-Verlag",
number = "10",

}

Smith, K, Gemmell, CG & Lang, S 2013, 'Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models', European Journal of Clinical Microbiology and Infectious Diseases, vol. 32, no. 10, pp. 1327-1332. https://doi.org/10.1007/s10096-013-1883-z

Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. / Smith, Karen; Gemmell, Curtis G.; Lang, Susan.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, No. 10, 10.2013, p. 1327-1332.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models

AU - Smith, Karen

AU - Gemmell, Curtis G.

AU - Lang, Susan

PY - 2013/10

Y1 - 2013/10

N2 - The activity of telavancin was compared with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in planktonic culture and biofilms grown using a range of in vitro models. Antibiotic efficacy was determined using 24 clinical isolates, including healthcare-associated (HA)-MRSA, community-associated (CA)-MRSA and isolates with reduced (intermediate) susceptibility to vancomycin (VISA). Activity against biofilms was compared using three models: 96-peg plates, 96-well flat-bottom plates and a flow-cell system. Cell death was evaluated using a metabolic dye and Live/Dead staining.

AB - The activity of telavancin was compared with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in planktonic culture and biofilms grown using a range of in vitro models. Antibiotic efficacy was determined using 24 clinical isolates, including healthcare-associated (HA)-MRSA, community-associated (CA)-MRSA and isolates with reduced (intermediate) susceptibility to vancomycin (VISA). Activity against biofilms was compared using three models: 96-peg plates, 96-well flat-bottom plates and a flow-cell system. Cell death was evaluated using a metabolic dye and Live/Dead staining.

KW - telavancin

KW - vancomycin

KW - Staphylococcus aureus

KW - biofilms

U2 - 10.1007/s10096-013-1883-z

DO - 10.1007/s10096-013-1883-z

M3 - Article

VL - 32

SP - 1327

EP - 1332

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 10

ER -

Smith K, Gemmell CG, Lang S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. European Journal of Clinical Microbiology and Infectious Diseases. 2013 Oct;32(10):1327-1332. https://doi.org/10.1007/s10096-013-1883-z

Documents and Links